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Purpose: Fast-release gastroretentive solid dispersions of glibenclamide using gelucire were prepared 
to achieve improved bioavailability.  
Methods: Hot melt granulation technique was adopted to prepare solid dispersions (SDs) of 
glibenclamide in gelucire 50/13 and were compared with pure glibenclamide and physical mixtures of 
drug and gelucire using hot stage polarized microscopy, powder x-ray diffraction (PXRD), Fourier-
transform infrared spectroscopy FTIR, bouyancy as well as by in vitro release and in vivo studies. 
Further aging studies were carried out for the samples. 
Results: PXRD showed that glibenclamide was present in SD in an amorphous form while FTIR 
spectroscopy revealed the presence of hydrogen bonding in the SDs. In vitro buoyancy was found for 
11 h and there was improvement in solubility and dissolution rate for all test formulations. Formulations 
were found to follow Zero order kinetic. . During aging study,   no decrease of in vitro drug dissolution 
was observed over 3-month period.  Crystallinity in the SDs was observed following aging. A more 
pronounced lowering of blood glucose level in Wistar rats compared with the pure drug, suggests that 
the test formulations are superior.  
Conclusion:  This study demonstrates the high potential of hot melt technique for obtaining stable fast-
release gastroretentive solid dispersions of poorly water soluble drug using polyglycolized glycerides as 
carriers  
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INTRODUCTION 
 
The gastro-residence time of orally 
administered dosage form is generally short 
due to rapid gastric emptying. Rapid 
gastrointestinal transit could result in 
incomplete drug release from orally 
administered dosage form above the 
absorption zone, leading to diminished 
efficacy [1]. In order to increase the 
bioavailability of such drugs, the residence 
time of the orally administered dosage form in 
the upper gastrointestinal tract needs to be 
prolonged. The approaches to prolong 
gastroresidence time of pharmaceutical 
dosage forms include bioadhesive, 
mucoadhesive and density control delivery 
system [2-4].  
 
Recently, much attention has been focused 
on the use of fats and fatty acid as carriers in 
drug delivery systems [5-7]. Mahadik et al [8] 
demonstrated the use of amphiphilic lipid 
glyceryl monooleate for the design of floating 
matrix system. Gelucire is in the family of 
vehicles derived from mixtures of mono-, di- 
and tri-glycerides with PEG esters of fatty 
acids. These are available with a range of 
properties depending on their hydrophilic-
lipophilic balance (HLB) value and melting 
point range (33 - 65 ºC). These are used in 
the preparation of fast release and sustained 
release formulations. Gelucire containing only 
PEG esters are generally used in the 
preparation of fast release formulation. Owing 
to their extreme hydrophilicity and low 
density, Gelucire 50/13 may be considered 
an appropriate carrier for designing a fast 
release floating drug delivery system [9]. 
Glibenclamide is a poorly soluble drug with 
possible content uniformity problems and 
dissolution rate-limited bioavailability, is given 
in a therapeutic dose of 5 - 15 mg daily, has a 
half-life of around 10 h and exhibits low 
bioavailability. However, the bioavailability of 
the drug has been found to reduce further 
with conventional dosage forms probably due 
to the fact that passage of the single unit 
dosage form of the drug is faster than its 
release and most of the drug is released in 
the colon [10]. Therefore, it is desirable to 
improve on earlier formulations by developing 
fast release gastroretentive solid dispersion 
system. Solubility enhancement of gliben-
clamide is an important aspect of formulation 
development. Although there is a plethora of 
reports of solubility improvement using 
different techniques, a comparative study of 
different solubilization approaches are few 
[11]. Solubilization of poorly aqueous soluble 
drug forms an important activity in formulation 
process [12]. Therefore, the objective of this 
study was to design and develop, with the aid 
of solubilizers, glibenclamide formulation with 







Glibenclamide was received as a gift from 
Ranbaxy, Gurgaon, India. Gelucire 50/13 
(semi-synthetic polyglycolized glycerides) 
was provided by Gattefosse, St.Priest, 
Cedex, France. All other materials and 
reagents used were of analytical grade. 
 
Preparation of solid dispersions (SDs) and 
physical mixtures (PMs) 
 
Solubility enhancement of glibenclamide 
(GLB) was achieved by dispersing the drug in 
molten Gelucire 50/13 at various ratios (1:1, 
1:2, 1:4 and 1:10)[9]. It was poured on 
aluminium foil, allowed to solidify in a covered 
Petri dish and then kept in a refrigerator for 3 
h. The solid lump was passed through a fine 
mesh (150 µm) to obtain a fine powder 
formulation that was then placed in a calcium 
chloride desiccator for 48 h. The quantities of 
GLB, SDs and hydrophilic additives, namely, 
polyethylene glycol (PEG) 200, 400, 4000 
and 6000 used are as shown in Table 1. 
Physical mixtures (PMs) of drug and Gelucire 
were prepared by triturating them for 15 min 
followed by sieving through a 150 µm mesh. 
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Table 1:  Composition (mg) of glibenclamide formulations containing Gelucire 50/13 and PEGs 
 
Ingredient GI G II G III G IV G V G VI G VII G VIII G IX 
GLB 5 5 5 5 5 5 5 5 5 
PEG 200 - 5 - - - 10 - - - 
PEG 400 - - 5 - - - 10 - - 
PEG 4000 - - - 5 - - - 10 - 
PEG 6000 - - - - 5 - - - 10 
Gelucire 50/13 50 50 50 50 50 50 50 50 50 
Total 55 60 60 60 60 65 65 65 65 
 
Determination of drug content of SDs 
 
SDs equivalent to 5 mg of GLB were weighed 
accurately and dissolved in a suitable 
quantity of methanol. After filtration through a 
0.45 µm filter (Ashless-Whatman, England), 
drug content was determined at 229 nm by 
spectrophotometry (Shimadzu UV-1800, 
Japan) with suitable dilution. Absorbance 
determination was performed in triplicate. 
 
Evaluation of saturation solubility  
 
The saturation solubility of GLB, PMs and 
SDs was evaluated by adding known excess 
amount of GLB formulation or pure GLB to 10 
ml of 0.1M HCl (pH 1.2), stirred at 20 rpm in a 
water bath (25 ± 0.3 ºC) for 48 h, filtered, 
diluted suitably with 0.1M HCl (pH 1.2) and 
analyzed at 229 nm. 
 
Hot stage polarized microscopy (HSPM)  
 
About 2 mg of sample was placed on a glass 
slide and covered with cover slip. The slide 
was examined under optical microscope fitted 
with a hot stage, heated at a rate of 2 º C/min 
from room temperature to 50 ºC where it was 
held for 30 min, and then cooled to 40 ºC. It 
was held at this temperature for 30 min. 
Polarized light microscopy was applied for 
the detection of crystallinity [13].  
 
Powder x-ray diffraction (PXRD)  
 
X-ray diffraction studies on GLB, Gelucire 
50/13, PMs and SDs were determined using 
a D8 Advance, Bruker AXS instrument with a 
nickel-filtered radiation. The samples were 
irradiated with monochromatized CuK (α) 
radiation (1.542 Å) and analyzed between 2 º 
and 50 º 2θ using a step scan mode (step 
width = 0.020 º (2θ), counting time = 0.5 
s/step). Diffraction peak (d) intensities and 2 
h values of the SDs patterns were compared 
to those of the pure materials in order to 
evaluate the physical form of GLB in the 
samples. 
 
Fourier-transform infrared spectroscopy 
(FTIR)  
 
FTIR spectra of the individual materials as 
well as SDs were obtained, after appropriate 
background subtraction, using FTIR-8400 
spectrometer (Shimadzu, Japan). About 2 – 3 
mg of the sample was triturated with dry 
potassium bromide, compressed into disc 
and scanned from 4000 – 400 cm−1. 
 
Evaluation of in-vitro buoyancy  
 
In vitro bouyancy assessment was performed 
using a USP dissolution apparatus type II by 
placing the SD in 900 ml of 0.1M HCl (pH 
1.2) at 37.0 ± 0.5 ºC and then agitated with a 
paddle at 75 rpm for 12 h. After agitation, the 
lipid particles that floated on the surface of 
the medium as well as those that settled at 
the bottom of the flask were removed 
separately. The proportion of floating 
particles was evaluated [14].  
 
In vitro drug release studies  
 
USP type II (paddle) method was used with 
the aid of Electrolab dissolution tester 
(TDT06 N, India). The dissolution medium 
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used was 900 mL of 0.1M HCl (pH 1.2) at 37 
± 0.5 °C and stirred at 75 rpm. An aliquot (5 
ml) was withdrawn at predetermined time 
intervals for 4 h and replaced with same 
volume of fresh medium. The withdrawn 
sample was suitably diluted and analyzed 
using a spectrophotometer at 229 nm; the 
test was also carried out on a commercial 
brand of fast-release glibenclamide tablet 
(Betanase®, Cadila Healthcare Ltd, India). 
 
Analysis of release kinetic and drug 
release mechanism  
 
The release data obtained were treated 
according to zero-order, first-order, Higuchi 
[15] and Korsmeyer-Peppas’s models [16] 
with the aid of PCP-Disso software (V3, 
Poona College of Pharmacy, Pune, India), in 
order to analyze the kinetics of drug release 
from the formulations. Higuchi (Eq 1) and 
Korsmeyer-Peppas (Eq 2) models were also 
applied to determine drug release 
mechanism. 
Q = Kt1/2 …………………………… (1) 
 
where Q is the amount of drug released in 
time, t,, and K is the release constant.  
Mt/M∞ = Ktn   ………………………….. (2) 
where Mt/M∞ is the fraction of drug released 
in time, t, K is the structural and geometric 
constant, and n is the release exponent [17].  
 
Effect of ageing   
 
The SDs were stored at 30 ºC/65 % RH for 3 
months and the effect of ageing on the SDs 
were studied by measuring their in vitro 
release as well as structural features using 
DSC and XRPD.  
 
Evaluation of blood glucose  
 
Blood glucose level (BGL) lowering studies of 
the SDs and pure GLBs were determined in 
streptozotocin (STZ)-induced diabetic Wistar 
rats of either sex weighing 150 – 200 g. The 
animals were handled as per CPCSEA 
Guidelines of Good Laboratory Practice 
(GLP) [18]. They were housed in 
polypropylene cages with free access to 
standard laboratory diet and water. The 
research protocol of the animal 
experimentation (registration no. 837/ac/04/ 
CPCSEA, resolution no. 20/PhD/2008-2009, 
dated 8 March 2010) was approved by the 
‘Institutional Animal Ethical Committee’ of 
College of Pharmacy, IFTM, Moradabad-
244001, Uttar Pradesh, India. The animals 
were divided into 4 groups.  Group I (control) 
was given 2 ml saline p.o. Diabetic control 
(Group II) was given STZ 35 mg/kg i.p. in 
citrate buffer (pH 4.5). Diabetic standard 
treatment Group III was given pure GLB (0.25 
mg/kg) in aqueous solution p.o through an 
oral cannula. Diabetic test treatment (Group 
IV) was given GLB formulation (optimized 
batch) equivalent to 0.25 mg/kg of GLB p.o. 
in 2 ml of 1 % sodium carboxylmethyl 
cellulose via an oral cannula. Blood glucose 
level (BGL) was measured periodically using 
Ascensia Entrust Glucometer (Bayer 
HealthCare, USA). 
 
Statistical analysis  
 
Statistical analysis of the data was carried out 
by Student’s t-test and one-way analysis of 
variance (ANOVA) at a significance level of p 




Saturation solubility  
 
The saturation solubility of GLB was 18.9 
µg/ml while the enhanced saturated solubility 
obtained using drug:Gelucire (1:1) in physical 
mixture and solid dispersion was  27.23 and 
44.39 µg/ml, respectively. Drug solubility 
increased in direct proportion to the 
proportion of Gelucire 50/13 in the 
preparations. Based on saturation solubility, 
ratio 1:10 showed enhanced solubility.  
 
Hot stage polarized microscopy (HSPM)  
 
HSPM of the SDs showed continuous melting 
from room temperature to 50 ºC and when it 
was cooled back to 40 ºC. Change in 
physical   form   was   observed   at   different  
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Fig 1: Typical photomicrographs of solid dispersions (SDs) showing physical changes as temperature is 
varied  
 
temperatures as shown in the 
photomicrographs in Fig 1.. The 
photomicrographs indicate that large crystals 
of pure GLB were reduced to small particle 





The x-ray diffractograms of pure GLB (Fig 2a) 
had prominent diffraction peaks (d) equal to 
8.035 º, 7.464 º, 4.649 º, 3.860 º, 2.933 º and 
1.687 º, respectively on 2θ scale, which 
indicates its crystalline nature. The 
diffractograms for the formulations and 
Gelucire 50/13 (Fig 2b) indicate that GLB 
peaks decreased, suggesting its conversion 
from a crystalline to an amorphous state; 
diffractograms for the formulations physical 
mixtures and solid dispersions (Fig 2 (c) and 
(d)) indicate that GLB peaks decreased, 
suggesting its conversion from crystalline to 
an amorphous state; Gelucire 50/13 showed 
two prominent diffraction peaks (d) of 4.61 º 
and 3.81 º with the highest intensity on 2θ 
scale. The principal peaks of Gelucire 50/13 
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were present in both PMs and SDs with a 
lower intensity. The diffractogram of SDs 
showed absence of any trace of crystallinity, 
indicating the existence of amorphous GLB. 
 
 
Fig 2: X-ray diffractogram of (a) pure GLB, (b) 
Gelucire 50/13, (c) physical mixtures (PMs) and 
(d) solid dispersions (SDs)  
 
Fourier transform infrared (FTIR) spectra 
 
FTIR spectra of pure GLB showed 
characteristic amide peaks at 3367.48, 
3315.41, 2929.67, 2854.45 and 1716.53 cm-
1; urea carbonyl stretching (urea NH 
stretching) vibration at 1618.2 and 1521.73 
cm-1; and SO2 stretching vibration at 1340.43 
and 1159.14 cm-1. On the other hand, the 
FTIR spectra of PMs showed slight intense 
amide peaks at 3315.41 and 1716.53 cm-1, 
while SDs showed almost complete 
disappearance of amide peaks at 3315.41 
and 1716.53 cm-1, and concomitant shift to 
higher frequencies of urea carbonyl 
stretching vibration at 1618.2 and 1521.73 to 





Fig 3: Comparative in vitro drug release of (A) SD 
formulations (◊ = G1, □ = G2, ○ = G3, ∆ = G4.  = 
G5, ● = G6, × = G7, ▲ = G8; and (B) optimized 
SD (▲) and a commercial GLB brand, Betanase® 
(□).                      
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Table 2: Release kinetic data for GLB solid dispersions (SDs) based on various models 
 










GI 0.6893  0.9531   0.9874  0.9116 0.8378 
G II 0.6673  0.9152  0.9707  0.8939 0.8054 
G III 0.7200  0.9463  0.9722  0.9266 0.8398 
G IV 0.8005  0.9265  0.9888  0.9714 0.8384 
G V 0.7238  0.9750  0.9611  0.9334 0.8246 
G VI 0.7506  0.9210  0.9710  0.9462 0.9221 
G VII 0.6927  0.9732  0.9742  0.9131 0.9180 
G VIII 0.6959  0.9585  0.9915   0.9162 0.8258 
G IX 0.7072  0.8990  0.9288  0.9135 0.8119 
 Note: Formulation code as in Table 1; r2 = regression coefficient. 
 
In vitro buoyancy, and drug entrapment 
and release 
 
In vitro release profiles of the GLB SDs 
formulation in simulated gastric (pH 1.2) are 
shown in Fig 3A). In vitro buoyancy results 
indicate that the SD formulation remained 
floating for 11 h while drug entrapment 
efficiency was as high as 99.8 %. The 
regression coefficient (r2) data based on 
kinetic analysis using various release models 
are listed in Table 2. The formulations were 
best fitted to the zero-order release model, 
with r2 close to one. Korsmeyer-Peppas n 
data also indicate that the drug release 
mechanism was non-Fickian case II diffusion-
controlled with n values ranging from 0.80 to 
0.9221). The in vitro release data of 
optimized test GLB solid dispersion and 
commercial reference brand (Betanase® 
tablet) are indicated in Fig 3B. Release 
profiles of the two preparations were 
comparable. 
 
Effect of ageing 
 
When the GLB SDs were kept at 30 ºC / 65 
%RH for 3 months, no change in in vitro drug 
dissolution was observed, compared with the 
initial release rate.  
 
 
Effect of GLB SDs on blood glucose level 
 
As shown in Fig 4 the hypoglycemia 
produced in diabetic treated group IV treated 
with SD was significantly higher (p < 0.01) 
than the diabetic standard (GLB) treated 
group III. The Blood glucose level in diabetic 
treated  group IV in 4 h were  the same with 
Control group I compared with diabetic  group 





Fig 4: In vivo blood glucose lowering properties of 
optimized SD formulation in wistar rats. Key:  (1) = 
Normal control, (2) = Diabetic control II, (3) = 
Diabetic standard treatment, and (4) Diabetic SD 
treatment 
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DISCUSSION 
 
Hot melt granulation technique was selected 
to achieve solid dispersion, as it has been 
successfully utilized to increase the solubility 
of GLB [1]. PEGs and Gelucire are among 
the several carriers that have been employed 
in preparing solid dispersions.  
 
The purpose of the current study was to 
examine the solid-state properties of a solid 
dispersion system of GLB prepared using 
Gelucire 50/13 and various grades of PEGs 
at varying ratios. Intermolecular interaction 
such as hydrogen bonding between the 
amide of GLB and the oxygen of polyglycol 
chain (Gelucire) inducing a shift of N-H 
vibration to an extent that depends on the 
strength of interaction. The site of the 
interaction on Gelucire would probably have 
been C=O group, which would also affect N-
H vibration. This observation agrees with the 
data generated from PXRD and FTIR studies.  
 
Both HSPM and x-ray diffraction analysis 
revealed that GLB was in an amorphous 
state and uniformly distributed throughout 
matrix while FTIR spectroscopy revealed the 
possibility of H-bonding interaction in both 
PMs and SDs.  
 
To achieve gastro-retention, the time needed 
for the initiation of floatation (floating lag time) 
was less than 3 min for all the SD 
formulations. However, maximum in vitro 
buoyancy was 11 h. SDs exhibited 
dramatically improvement in initial rate as 
well as extent of in vitro drug dissolution. 
Zero-order kinetics model fitted best for the 
formulations while the n exponent of the 
Korsmeyer-Peppas model indicate that 
erosion was the mechanism of drug release. 
Release of drug from hydrophilic mini-
matrices generally involves both pore 
diffusion and matrix erosion [5]. Low density 
and hydrophilic property due to the higher 
HLB of Gelucire 50/13 facilitated 
gastroretension and drug dissolution. 
Gelucire 50/13 possesses surfactant and 
self-emulsifying property and is also used as 
meltable binder by melt granulation of poorly 
water soluble active substances [9]. In 
contact with aqueous fluids, it forms a fine 
emulsion, solubilizes the active substance 
and hence increases its oral bioavailability.  
 
Incorporation of GLB in the Gelucire 50/13 
led to the formation of a solid dispersion 
system with increased dissolution rate of the 
drug due to improved wettability and the 
additional presence of a self-emulsifying 
compound, PEG. Moreover, it also increased 
the dispersability of the hydrophobic drug in 
the hydrophilic carrier during the process of 
solid dispersion formation. Thus, the increase 
in the dissolution of the drug can be 
attributable to improvement in wetting and to 
local solubilization by the excipients in the 
diffusion layer. The SDs exhibited higher 
burst release due probably to enhanced 
wettability of the drug particles, the 
emulsifying effect of carriers, significant 
reduction in particle size during SD formation 
and/or the inherently higher dissolution rate 
of soluble component of the SDs, which 
would pull along the more insoluble but finely 
mixed drug into the dissolution medium. 
Improved drug dissolution could also be 
attributed to the presence of the amorphous 
form of GLB, as indicated by the x-ray 
diffraction findings.  
 
The increase in the release rate of the GLB 
SDs was also reflected in vivo by the greater 
reduction in blood glucose level in Wistar rats 




The present study demonstrates the high 
potential of hot melt-granulation technique for 
the production of solid dispersions of 
glibenclamide using polyglycolized glycerides 
as carriers. However, further studies are 
required to develop the formulation to 
industrial scale production. 
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